We focused on building differential gene co-expression networks across ER positive (ER+) and ER negative (ER-) patients because of ER’s prognostic value in profiling breast cancer patients [72]: cancer patients that are ER+ are more likely to respond to endocrine therapies than patients that are ER-. This evidence concerns the gene ESR1 and breast cancer.